Nearly 10 years after the first JAK inhibitor was approved for a dermatologic disorder, more uses are imminent, with fewer ...

Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...

The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biotechnology company developing next-generation ...

JAK inhibitor treatment is not associated with stunted growth in children with common inflammatory diseases, according to a ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...

Patients with alopecia areata (AA) who do not respond to treatment with one of the three approved JAK inhibitors may get a response by switching to one of the other JAK inhibitors, a small study has ...

Please provide your email address to receive an email when new articles are posted on . Acne was an adverse event for 6.2% of patients treated with Janus kinase (JAK) inhibitors vs. 1.3% of controls.

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to infiltration by ...

Over the last decade, research and development of Janus kinase (JAK) inhibitors have exploded. Three years ago, JAK inhibitors were on the cusp of being available for dermatologic indications. In this ...

While the treatment landscape has really exploded since the early days, there aren't any non-JAK inhibitors approved yet. Here, Prithviraj Bose, MD, professor in the Department of Leukemia at the ...

Newer oral medications for rheumatoid arthritis (RA) do work quite well in the "real world," despite some doubts that they would, according to a new study. The study, of 622 adults with RA, found that ...